Compare WAVE & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WAVE | NEPH |
|---|---|---|
| Founded | 2011 | 1997 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.5M | 49.4M |
| IPO Year | 2021 | 2004 |
| Metric | WAVE | NEPH |
|---|---|---|
| Price | $5.89 | $4.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 9.6K | ★ 31.8K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1000.00 |
| EPS | N/A | ★ 0.12 |
| Revenue | N/A | ★ $18,789,000.00 |
| Revenue This Year | $436.84 | $11.24 |
| Revenue Next Year | N/A | $11.58 |
| P/E Ratio | ★ N/A | $34.71 |
| Revenue Growth | N/A | ★ 32.67 |
| 52 Week Low | $4.52 | $2.66 |
| 52 Week High | $10.87 | $6.42 |
| Indicator | WAVE | NEPH |
|---|---|---|
| Relative Strength Index (RSI) | 37.21 | 50.67 |
| Support Level | $5.53 | $3.98 |
| Resistance Level | $6.49 | $4.26 |
| Average True Range (ATR) | 0.44 | 0.39 |
| MACD | -0.03 | -0.05 |
| Stochastic Oscillator | 28.30 | 35.32 |
Eco Wave Power Global AB is a Sweden-based wave energy company engaged in the development of a smart and cost-efficient wave energy conversion, or WEC, technology that converts ocean and sea waves into clean electricity. Its WEC technology employs units of point absorber floating devices, referred to as floaters, which are installed on existing marine structures such as piers, breakwaters, and jetties, or in locations in which such marine structures are required. Geographically, it has a presence in Israel, the USA, and Mexico.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.